Medicovestor, Inc.
BiotechnologyBiopharmaceutical ADC Development
New York, NY
About
Medicovestor is an early-stage biopharmaceutical company founded in 2023, focused on developing next-generation antibody-drug conjugate (ADC) platforms. The company aims to create precision medicines for solid tumors like pancreatic and ovarian cancer by overcoming the limitations of existing ADCs, particularly in tumors with low antigen expression.
Company Values
The company's core innovation is its proprietary dimeric ADC platform, which is designed to functionally increase tumor antigen density and utilizes backbone antibodies with intrinsic antitumor activity, enabling a multi-pronged attack on cancer cells.